# Harvard Bioscience, Inc. (HBIO)

> Source: Nexqual · https://nexqual.com/HBIO · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Harvard Bioscience, Inc. (HBIO), nexqual.com/HBIO" · informational, not investment advice.

**Price:** USD 8.31 (+1.96% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 8.15 · day 7.95–8.4 · 52w 3.8–9.4 · market cap $37.8M · NCM

## Key facts
- Analysts: Buy (mean 2.00 on a 1–5 scale) (2 analysts), mean target USD 7.5 (range 7.5–7.5).
- Total return with dividends: 1Y +107.8% vs S&P 500 +18.1%; 5Y -87.8% vs S&P 500 +85.1%.
- Next earnings: 2026-11-10, EPS estimate USD -0.17, revenue estimate $21.8M.

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 2 analysts; mean target USD 7.5 (low 7.5, high 7.5).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-12 | Benchmark | Target raised | Speculative Buy | $6 → $7.5 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | +107.8% | -87.8% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +108.3% | -34.3% |
| Volatility (annualized) | 85.9% | 68.9% |
| Max drawdown | -45.4% (Dec 2025→Apr 2026) | -96.1% (Nov 2021→May 2025) |

## Peers (Medical Instruments & Supplies)
KMTS (Kestra Medical Technologies, Lt) USD 28.68 +6.34% · XRAY (DENTSPLY SIRONA Inc.) USD 8.83 +3.76% · LMAT (LeMaitre Vascular, Inc.) USD 83.16 +1.97% · ATRC (AtriCure, Inc.) USD 57.78 +1.60% · WRBY (Warby Parker Inc.) USD 24.59 -7.28% · PLSE (Pulse Biosciences, Inc) USD 45.59 -6.08%

## More
Full page: https://nexqual.com/HBIO · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt